21st July 2016, SomnoMed Limited (ASX:SOM) announced today that continuing strong Q4 growth in direct sales volume allowed it to generate unaudited quarterly group revenues of $11.6 million (+ 28.6%) and total group revenues for the 2015/16 financial year of $44 million, representing an annual growth of +27.7%.
Q4 direct sales reached a record 14,965 units (+21.8%) globally. Direct quarterly sales in North America grew by 25.6%, whilst Europe posted a growth of 22.9% and APAC/Japan grew by 2.5% in the quarter. Within the APAC region, in the last quarter of the financial year Japan delivered a unit sales growth of 18.4% and South Korea of 27.6%.
As expected, sales through licensees in North America continued to drop in Q4 by 54.2%, bringing total sales for the quarter to 15,989 devices (+10.1%).
For further information, please download pdf provided:
Download this document
